eISSN 2287-9803 
pISSN 2287-9412 
Aims and Scope
Ethical Guidelines
Editoral Board
Forthcomming Issue
Current Issue
Most Read Articles
Informaion for Authors
Check List
Contact us
Original Article
  |     |   Neonatal Med_20_2_207_213.pdf
Neonatal Med May;20(2):207-213.
Published online 2013 June 26   doi: https://doi.org/10.5385/nm.2013.20.2.207
Copyright ⓒ 2013 Neonatal Medicine Neonatal Medicine
Comparison of Curosurf® versus Surfacten® in the Treatment of Respiratory Distress Syndrome
Jeong Nam Kim, M.D., and Eun Jung Shim, M.D.
Department of Pediatrics, College of Medicine, Hallym University, Anyang, Korea
Corresponding Author: Eun Jung Shim, M.D. , Tel: +82-31-380-3730 , Fax: +82-31-380-3733 , Email: baby4019@hallym.or.kr
This article has been corrected. See Neonatal Med. 2013 November; 20(4): 480.
Purpose: The goal of this study was to compare the effects of treatment of newborn babies with two different surfactants, Curosurf® and Surfacten®.
Methods: We retrospectively reviewed the medical records from 2007 to 2009 and divided the patients into two groups: those who received Curosurf® (n=20) and those who received Surfacten® (n=21). We compared the groups for sex, gestational age (GA), birth weight, type of delivery, apgar score, maternal history, age at treatment, bronchopulmonary dysplasia (BPD), administration indomethacin for patent ductus arteriosus(PDA), necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH), periventricular leucomalacia (PVL), retinopathy of prematurity (ROP), pulmonary hemorrhage (PH), pneumothorax (PTX), duration of ventilation, need for oxygen, and administration.
Results: The demographic and clinical variables were similar in both groups. The gestational age for Curosurf® and Surfacten® were 32.7±3.1 and, 30.5±4.3 weeks, respectively (P=0.08). Six newborns in the Curosurf® group and 8 in the Surfacten® group developed BPD (P=0.59). No significant differences were noted for NEC, IVH, PVL, ROP, PH, PTX between the two groups (IVH, P=0.14; PVL, P=0.94; ROP P=0.94; PTX P=0.34). The mean duration of ventilation was 16.8 days with Curosurf® and 23.7 days with Surfacten®, but these differences were not statistically significant (P=0.43). The differences in duration of need for oxygen and administration were also not statistically significant (P=0.92, 0.91, respectively).
Conclusion: This study indicated no significant differences between Curosurf® and Surfacten®. However, because of its convenience and the merit of minimal touching of the babies, the use of Curosurf® is recommended.
Keywords: Curosurf®, Surfacten®, Respiratory distress syndrome, Surfactant treatment
Copyright(c) By Korean Society of Neonatology. All right reserved.
Rm.1207, King's garden 3 Block, 34, Sajik-ro 8-gil, Jongno-gu, Seoul 110-872, Korea. TEL: +82-2-730-1993 FAX: +82-2-730-1994 Email:neonate2002@hanmail.net